Today, Boehringer Ingelheim announced the 24-week results from the Phase III VOLTAIRE®-RA study, comparing the adalimumab biosimilar candidate BI 695501 to Abbvie’s Humira® in patients with moderate- to severely-active rheumatoid arthritis. According to BI, the results indicate that BI 695501 has similar efficacy, safety, and immunogenicity as Humira® in these patients. The results will be presented at the Annual European Congress of Rheumatology (EULAR 2017) in Madrid.
The post Boehringer Ingelheim Announces Interim Results on Adalimumab Biosimilar Candidate BI695501 appeared first on Big Molecule Watch.